Nichols & Pratt Advisers LLP MA Acquires 2,899 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nichols & Pratt Advisers LLP MA lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,144 shares of the medical research company's stock after acquiring an additional 2,899 shares during the quarter. IQVIA makes up approximately 1.4% of Nichols & Pratt Advisers LLP MA's portfolio, making the stock its 24th biggest position. Nichols & Pratt Advisers LLP MA owned 0.06% of IQVIA worth $21,448,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Metis Global Partners LLC increased its position in IQVIA by 19.5% in the 4th quarter. Metis Global Partners LLC now owns 10,023 shares of the medical research company's stock valued at $1,970,000 after acquiring an additional 1,633 shares during the period. Fisher Asset Management LLC raised its position in IQVIA by 112.2% during the 4th quarter. Fisher Asset Management LLC now owns 15,696 shares of the medical research company's stock worth $3,085,000 after purchasing an additional 8,298 shares during the last quarter. SVB Wealth LLC acquired a new position in IQVIA during the 4th quarter worth about $5,042,000. Mutual of America Capital Management LLC grew its position in shares of IQVIA by 49.8% in the 4th quarter. Mutual of America Capital Management LLC now owns 32,030 shares of the medical research company's stock valued at $6,294,000 after buying an additional 10,655 shares during the last quarter. Finally, Bruni J V & Co. Co. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $13,304,000. Institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on IQV. Leerink Partners reissued an "outperform" rating and set a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Stifel Nicolaus cut their price target on shares of IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. UBS Group lowered their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. decreased their target price on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Stock Up 1.3 %

NYSE:IQV traded up $2.47 during trading hours on Wednesday, hitting $186.04. 1,050,048 shares of the company traded hands, compared to its average volume of 1,206,530. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $32.76 billion, a PE ratio of 24.81, a PEG ratio of 1.99 and a beta of 1.48. The firm's 50-day simple moving average is $198.52 and its 200-day simple moving average is $213.86. IQVIA Holdings Inc. has a one year low of $179.28 and a one year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.